source
- Pfizer CEO warns China will be major biotech competitor by 2030 and urges AI-driven cost cutsAt the Jefferies Global Healthcare Conference in London, Pfizer chief Albert Bourla said China is rapidly building its biotech sector and could become the company's biggest rival by 2030, surpassin…
- FDA rejects Summit Therapeutics' ivonescimab, citing trial design and safety concernsSummit Therapeutics received a Complete Response Letter from the FDA rejecting its application for ivonescimab, a PD-1xVEGF combination intended for EGFR-mutated non-small cell lung cancer. The ag…